Cabbacis Inc
OOTC:CABI2.00
USD
+0.35
(+21.21%)
ISIN
US1269651022
CUSIP
126965102
Return %
Stock
S&P 500
1Y
-11.11
14.39
3Y
- -
81.42
5Y
- -
68.62
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Semi-annual Revenue
FRC
•
in mil. unless spec.Semi-annual Earnings Per Share
FRC
•
in mil. unless spec.Semi-annual Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Joseph Pandolfino
- Sector
- Consumer non-durables
- Industry
- Tobacco
- Address
- Niagara Falls United States
- IPO Date
- Nov 1, 2024
- Website
- cabbacis.com
- Similar Companies
- Business
- Cabbacis Inc. is a development-stage plant biotechnology and federally licensed tobacco product manufacturing company focused on developing harm-reduction and reduced-nicotine consumer products. Founded in 2021 and headquartered in Niagara Falls, New York, the company operates through its wholly owned operating subsidiary, Cabbacis LLC, targeting domestic and international adult tobacco consumers seeking reduced nicotine exposure. The company's core product portfolio and pipeline include iBlend, a proprietary line of combustible cigarettes and vaporizer pods formulated with very-low-nicotine tobacco blended with industrial hemp containing less than 0.3% THC to deliver a standard smoking sensory profile while reducing nicotine content by approximately 95%; X95, a line of very-low-nicotine combustible cigarettes manufactured without hemp to serve markets where hemp additives are restricted or where non-hemp tobacco formulations are preferred; and plant biotechnology assets encompassing proprietary genetic, agronomic, and processing intellectual property governing reduced-nicotine alkaloid traits and hemp-tobacco blending methods. In recent corporate developments, Cabbacis completed a corporate reorganization via share exchange in August 2023, establishing Cabbacis LLC as a wholly owned subsidiary, and subsequently commenced public trading on the OTCQB Venture Market under the ticker symbol CABI in November 2024. The company has continued to expand its international intellectual property portfolio to 36 issued patents across key jurisdictions including the United States, Europe, China, Japan, and Canada, while advancing regulatory readiness and preparations for U.S. Food and Drug Administration marketing pathways, including Premarket Tobacco Product Applications and Modified Risk Tobacco Product submissions.